Metagen Therapeutics

Tokyo, Japan Founded: 2020 • Age: 6 yrs
CRO focused on providing microbiome drug discovery and development services

About Metagen Therapeutics

Metagen Therapeutics is a Healthcare company based in Tokyo (Japan) founded in 2020 by Shinji Fukuda, Takuji Yamada, Masatsugu Fukuda, Taku Nakahara, and Dai Ishikawa. CRO focused on providing microbiome drug discovery and development services. Metagen Therapeutics has raised $38.61 million across 10 funding rounds from investors including Keio Innovation Initiative, JAFCO and JIC Venture Growth Investments. Its chief executive, as recorded, is Taku Nakahara. Its website metagentx.com draws about 10 thousand monthly visits. Its focus areas include Biopharma Outsourcing, CRO, Drug Discovery and Cell and Molecular Biology.

Company details

Metagen Therapeutics was established in 2020 in Tokyo, Japan, as a contract research organization (CRO) specializing in the microbiome sector. Drug discovery and development services for microbiome-based therapeutics are delivered to clients in the pharmaceutical industry. Operations center on advanced research methodologies to identify and validate microbial targets. The companys activities support early-stage to preclinical pipeline advancement, with a focus on therapeutic applications in human health.

  • Headquarters Tokyo, Japan
  • Founders Shinji Fukuda, Takuji Yamada, Masatsugu Fukuda, Taku Nakahara, Dai Ishikawa
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website metagentx.com
  • Social LinkedIn X Facebook
Key Metrics
  • Total Equity Funding
    $38.61M (USD)

    in 10 rounds

  • Latest Funding Round
    $1.87M (USD), Series B

    Sep 2026

  • Investors

Funding Insights of Metagen Therapeutics

Metagen Therapeutics has successfully raised a total of $38.61M across 10 strategic funding rounds. The most recent funding activity was a Series B round of $1.87 million completed in September 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $38.61M
  • Total Rounds 10
  • Last Round Series B β€” $1.87M
  • First Round $827,640

    (Mar 2021)

  • Investors Count 24

All 10 funding rounds of Metagen Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Sep 2026$1.87MSeries B––
Sep 2026$1.28MSeries B––
Feb 2026$7.62MSeries B––
Sep 2025$15.72MSeries B–FTI
Jul 2025$10.24MSeries B––
–
Jun 2023Series A–JAFCO Group, FTI
Apr 2023Seed–JIC Venture Growth Investments
–
Jul 2022$679,000Seed––
–
Jun 2022$372,750Seed––
–
Mar 2021$827,640Seed––
–
Valuation history

24 investors in total: 24 institutional.

Investors in Metagen Therapeutics

Metagen Therapeutics has secured backing from 24 investors, including venture fund and institutional investors. Prominent investors backing the company include Keio Innovation Initiative, JAFCO and JIC Venture Growth Investments.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital fund focused on growth stage companies
j-vgi.co.jpMinato City, Japan
fasttrackinitiative.com
Stage-agnostic investments in Japanese tech and life sciences are made.
2015keio-innovation.co.jpTokyo, Japan
PE and VC fund focused on multiple sectors
1973jafco.co.jp/englishSingapore, Singapore
mizuho-vc.co.jp
smbc-vc.co.jp
Venture capital investments are made in research-driven startups.
2014miraisozo.co.jpTokyo, Japan
Venture capital firm investing in global startups with a focus on innovation and business support.
dentsu-v.com
fvc.co.jp
nvcc.co.jp
Premium access

Investor details for Metagen Therapeutics

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Metagen Therapeutics

5 people are tracked at Metagen Therapeutics (5 in leadership).

NameRoleGroup
Shinji Fukuda
Co-FounderLeadership
Takuji Yamada
Co-Founder & CTOLeadership
Masatsugu Fukuda
Co-FounderLeadership
Taku Nakahara
Co-Founder & CEOLeadership
Dai Ishikawa
Co-Founder & CMOLeadership
Premium access

Complete people profiles for Metagen Therapeutics

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Metagen Therapeutics

3 dated milestones of Metagen Therapeutics across 6 years, from founding to its latest funding, stage changes and deals.

  1. Founded Metagen Therapeutics is founded.
  2. Funding First funding round of $828K.
  3. Funding Latest funding round, Series B, of $1.9M.

Web traffic of Metagen Therapeutics

The website of Metagen Therapeutics (metagentx.com) receives about 10.1K visits a month.

  • Monthly visits
    10.1K

    ▲ 33.8% vs previous month

Similar websites

Websites whose visitors overlap most with Metagen Therapeutics. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
digireha.com
100%
3.2K#5,653,338View details
metagen.co.jp
72%
7.3K#2,679,295View details
storynews.jp
storynews.jp
60%
#3,704,544–
kindai-geka.jp
kindai-geka.jp
27%
#2,473,473–
22cemit.org
22cemit.org
26%
#6,258,342–
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Metagen Therapeutics

Premium access

Complete news archive for Metagen Therapeutics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Metagen Therapeutics

Metagen Therapeutics was founded in 2020 and raised its 1st funding round 1 year after it was founded.

Metagen Therapeutics is headquartered in Tokyo, Japan. It is registered at Tokyo, Tokyo, Japan.

Taku Nakahara is the CEO of Metagen Therapeutics, as recorded in our data. They have also founded this company.

Metagen Therapeutics is a funded company, having raised a total of $38.61M across 10 funding rounds to date. The company's 1st funding round was a Seed of $827.64K, raised on Mar 2021.

Metagen Therapeutics was established in 2020 in Tokyo, Japan, as a contract research organization (CRO) specializing in the microbiome sector. Drug discovery and development services for microbiome-based therapeutics are delivered to clients in the pharmaceutical industry. Operations center on advanced research methodologies to identify and validate microbial targets. The companys activities support early-stage to preclinical pipeline advancement, with a focus on therapeutic applications in human health.

Metagen Therapeutics has 24 investors. Key investors include Keio Innovation Initiative, JAFCO, JIC Venture Growth Investments, JAFCO Group, and FTI.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available